Search Results - "Pisters, Peter W. T."

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial by DeMatteo, Ronald P, Prof, Ballman, Karla V, PhD, Antonescu, Cristina R, MD, Maki, Robert G, MD, Pisters, Peter WT, Prof, Demetri, George D, MD, Blackstein, Martin E, MD, Blanke, Charles D, Prof, von Mehren, Margaret, MD, Brennan, Murray F, Prof, Patel, Shreyaskumar, Prof, McCarter, Martin D, MD, Polikoff, Jonathan A, MD, Tan, Benjamin R, MD, Owzar, Kouros, PhD

“…Summary Background Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small molecule that inhibits…”
Get full text

Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design by Katz, Matthew H. G., Marsh, Robert, Herman, Joseph M., Shi, Qian, Collison, Eric, Venook, Alan P., Kindler, Hedy L., Alberts, Steven R., Philip, Philip, Lowy, Andrew M., Pisters, Peter W. T., Posner, Mitchell C., Berlin, Jordan D., Ahmad, Syed A.

“…Background Methodological limitations of prior studies have prevented progress in the treatment of patients with borderline resectable pancreatic…”
Get full text

Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement by Abrams, Ross A., Lowy, Andrew M., O’Reilly, Eileen M., Wolff, Robert A., Picozzi, Vincent J., Pisters, Peter W. T.

Get full text

Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma by RAUT, Chandrajit P, TSENG, Jennifer F, PISTERS, Peter W. T, EVANS, Douglas B, SUN, Charlotte C, HUAMIN WANG, WOLFF, Robert A, CRANE, Christopher H, HWANG, Rosa, VAUTHEY, Jean-Nicolas, ABDALLA, Eddie K, LEE, Jeffrey E

“…To better understand the impact of a microscopically positive margin (R1) on patterns of disease recurrence and survival after pancreaticoduodenectomy (PD) for…”
Get full text

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma by Katz, Matthew H. G., Wang, Huamin, Fleming, Jason B., Sun, Charlotte C., Hwang, Rosa F., Wolff, Robert A., Varadhachary, Gauri, Abbruzzese, James L., Crane, Christopher H., Krishnan, Sunil, Vauthey, Jean-Nicolas, Abdalla, Eddie K., Lee, Jeffrey E., Pisters, Peter W. T., Evans, Douglas B.

“…Introduction Actual 5-year survival rates of 10–18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use of multimodality…”
Get full text

Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial by Fleshman, James, Branda, Megan, Sargent, Daniel J, Boller, Anne Marie, George, Virgilio, Abbas, Maher, Peters, Walter R, Maun, Dipen, Chang, George, Herline, Alan, Fichera, Alessandro, Mutch, Matthew, Wexner, Steven, Whiteford, Mark, Marks, John, Birnbaum, Elisa, Margolin, David, Larson, David, Marcello, Peter, Posner, Mitchell, Read, Thomas, Monson, John, Wren, Sherry M, Pisters, Peter W. T, Nelson, Heidi

“…IMPORTANCE: Evidence about the efficacy of laparoscopic resection of rectal cancer is incomplete, particularly for patients with more advanced-stage disease…”
Get full text

Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors by Bednarski, Brian K., Araujo, Dejka M., Yi, Min, Torres, Keila E., Lazar, Alexander, Trent, Jonathan C., Cormier, Janice N., Pisters, Peter W. T., Lev, Dina Chelouche, Pollock, Raphael E., Feig, Barry W., Hunt, Kelly K.

“…Background Management of gastrointestinal stromal tumors (GISTs) has been transformed with tyrosine kinase inhibitors (TKIs). While data on optimal duration of…”
Get full text

Angiosarcoma of the breast by Vorburger, Stephan A., Xing, Yan, Hunt, Kelly K., Lakin, Gregory E., Benjamin, Robert S., Feig, Barry W., Pisters, Peter W. T., Ballo, Matthew T., Chen, Lei, Trent, Jonathan, Burgess, Michael, Patel, Shreyaskumar, Pollock, Raphael E., Cormier, Janice N.

“…BACKGROUND Angiosarcoma of the breast is a rare entity. The objectives of this study were to evaluate prognostic factors and determine outcomes in a large…”
Get full text

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators by Katz, Matthew H. G., Fleming, Jason B., Bhosale, Priya, Varadhachary, Gauri, Lee, Jeffrey E., Wolff, Robert, Wang, Huamin, Abbruzzese, James, Pisters, Peter W. T., Vauthey, Jean‐Nicolas, Charnsangavej, Chusilp, Tamm, Eric, Crane, Christopher H., Balachandran, Aparna

“…BACKGROUND: Experience with preoperative therapy for other cancers has led to an assumption that borderline resectable pancreatic cancers can be converted to…”
Get full text

Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here? by Katz, Matthew H. G., Pisters, Peter W. T., Lee, Jeffrey E., Fleming, Jason B.

Get full text

Histologic Grading of the Extent of Residual Carcinoma Following Neoadjuvant Chemoradiation in Pancreatic Ductal Adenocarcinoma: A Predictor for Patient Outcome by CHATTERJEE, Deyali, KATZ, Matthew H, GOMEZ, Henry F, ABBRUZZESE, James L, FLEMING, Jason B, HUAMIN WANG, RASHID, Asif, VARADHACHARY, Gauri R, WOLFF, Robert A, HUA WANG, LEE, Jeffrey E, PISTERS, Peter W. T, VAUTHEY, Jean-Nicolas, CRANE, Christopher

“…Several grading schemes for the extent of residual tumor in posttreatment pancreaticoduodenectomy (PD) specimens have been proposed. However, the prognostic…”
Get full text

Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection? by Tseng, William W., Madewell, John E., Wei, Wei, Somaiah, Neeta, Lazar, Alexander J., Ghadimi, Markus P., Hoffman, Aviad, Pisters, Peter W. T., Lev, Dina C., Pollock, Raphael E.

“…Background Well-differentiated (WD)/dedifferentiated (DD) liposarcoma is the most common soft tissue sarcoma of the retroperitoneum. The frequency of distant…”
Get full text

Preoperative Paclitaxel and Concurrent Rapid-Fractionation Radiation for Resectable Pancreatic Adenocarcinoma: Toxicities, Histologic Response Rates, and Event-Free Outcome by PISTERS, Peter W. T, WOLFF, Robert A, EVANS, Douglas B, JANJAN, Nora A, CLEARY, Karen R, CHARNSANGAVEJ, Chusilp, CRANE, Christopher N, LENZI, Renato, VAUTHEY, J. Nicolas, LEE, Jeffrey E, ABBRUZZESE, James L

“…To evaluate the toxicity of a preoperative regimen of paclitaxel and concurrent external-beam radiation therapy, pancreaticoduodenectomy, and electron-beam…”
Get full text

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head by EVANS, Douglas B, VARADHACHARY, Gauri R, CHARNSANGAVEJ, Chusilp, LANO, Elizabeth A, HO, Linus, LENZI, Renato, ABBRUZZESE, James L, WOLFF, Robert A, CRANE, Christopher H, SUN, Charlotte C, LEE, Jeffrey E, PISTERS, Peter W. T, VAUTHEY, Jean-Nicolas, HUAMIN WANG, CLEARY, Karen R, STAERKEL, Gregg A

“…We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD)…”
Get full text

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience by Cloyd, Jordan M., Katz, Matthew H. G., Prakash, Laura, Varadhachary, Gauri R., Wolff, Robert A., Shroff, Rachna T., Javle, Milind, Fogelman, David, Overman, Michael, Crane, Christopher H., Koay, Eugene J., Das, Prajnan, Krishnan, Sunil, Minsky, Bruce D., Lee, Jeffrey H., Bhutani, Manoop S., Weston, Brian, Ross, William, Bhosale, Priya, Tamm, Eric P., Wang, Huamin, Maitra, Anirban, Kim, Michael P., Aloia, Thomas A., Vauthey, Jean-Nicholas, Fleming, Jason B., Abbruzzese, James L., Pisters, Peter W. T., Evans, Douglas B., Lee, Jeffrey E.

“…Background The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal…”
Get full text

Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival by Tzeng, Ching-Wei D., Cao, Hop S. Tran, Lee, Jeffrey E., Pisters, Peter W. T., Varadhachary, Gauri R., Wolff, Robert A., Abbruzzese, James L., Crane, Christopher H., Evans, Douglas B., Wang, Huamin, Abbott, Daniel E., Vauthey, Jean-Nicolas, Aloia, Thomas A., Fleming, Jason B., Katz, Matthew H. G.

“…Barriers to multimodality therapy (MMT) completion among patients with resectable pancreatic adenocarcinoma include early cancer progression and postoperative…”
Get full text

A flexible‐hazards cure model with application to patients with soft tissue sarcoma by Xie, Can, Huang, Xuelin, Li, Ruosha, Pisters, Peter W. T.

“…In medical research, it is often of great interest to have an accurate estimation of cure rates by different treatment options and for different patient…”
Get full text

Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head by VARADHACHARY, Gauri R, WOLFF, Robert A, LEE, Jeffrey H, ROSS, William A, TAMM, Eric P, BHOSALE, Priya R, KRISHNAN, Sunil, DAS, Prajnan, HO, Linus, XIONG, Henry, ABBRUZZESE, James L, EVANS, Douglas B, CRANE, Christopher H, SUN, Charlotte C, LEE, Jeffrey E, PISTERS, Peter W. T, VAUTHEY, Jean-Nicolas, ABDALLA, Eddie, HUAMIN WANG, STAERKEL, Gregg A

“…We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy…”
Get full text

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy by Varadhachary, Gauri R, Tamm, Eric P, Abbruzzese, James L, Xiong, Henry Q, Crane, Christopher H, Wang, Huamin, Lee, Jeffrey E, Pisters, Peter W T, Evans, Douglas B, Wolff, Robert A

“…With recent advances in pancreatic imaging and surgical techniques, a distinct subset of pancreatic tumors is emerging that blurs the distinction between…”
Get full text

Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer by Tran Cao, Hop S., Balachandran, Alpana, Wang, Huamin, Nogueras-González, Graciela M., Bailey, Christina E., Lee, Jeffrey E., Pisters, Peter W. T., Evans, Douglas B., Varadhachary, Gauri, Crane, Christopher H., Aloia, Thomas A., Vauthey, Jean-Nicolas, Fleming, Jason B., Katz, Matthew H. G.

“…Background Venous resection may be required to achieve complete resection of pancreatic cancers. We assessed the ability of radiographic criteria to predict…”
Get full text